Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DWP10292 and UDCA in Healthy Male Subjects
NCT02622685Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of DWP10292 in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Composite of Pharmacokinetics at 24 hours. Started May 2015; status: completed.
02
Drugs
DWP10292
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02622685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622685.